Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Vicore Pharma AB logo — company profile

Vicore Pharma AB

Founded 2009 Sweden Sweden 41 employees Post Ipo Equity Total: $501.50M Biopharma, Biotechnology +1

General Information

Company Name Vicore Pharma AB
Founded Year 2009
Location Sweden Sweden +3
Employees 41
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Vicore Pharma AB moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Vicore Pharma AB

Vicore Pharma AB is a Swedish biopharmaceutical company founded in 2009 that focuses on developing drugs with disease-modifying potential for respiratory diseases. It is currently advancing Buloxibutid (C21), the first-in-class orally available small molecule angiotensin II type 2 receptor agonist, through phase 2a development for idiopathic pulmonary fibrosis (IPF). In addition, the company is developing Almee™, a digital therapeutic based on cognitive behavioral therapy, to address the psychological impact of living with pulmonary fibrosis, which has received Breakthrough Device Designation from the FDA. Vicore's unique expertise in ATRAG chemistry and biology is enabling the company to expand its pipeline with several new therapies across potential indications. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. Notably, the company recently secured a kr500.00M Post-IPO Equity investment on 09 June 2023, with leading investors including HBM Healthcare Investments, HealthCap, OrbiMed, AP4, Suvretta Capital Management, Swedbank Robur, Third Swedish National Pension Fund, and SEB (Skandinaviska Enskilda Banken). For more information, visit www.vicorepharma.com.

Taxonomy: pharmaceutical company, clinical-stage, respiratory diseases, idiopathic pulmonary fibrosis, ATRAG, phase 2a development, digital therapeutic, breakthrough device designation, drug development, orphan drug designation, rare diseases, Nasdaq Stockholm, Astra Zeneca, bioventurehub, innovative medicines

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 8
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		09 Jun 2023
Grant •••••• 1
Investor
03 Jun 2020

Vicore Pharma AB Alternatives & Competitors

Vicore Pharma AB vs
Endeavor BioMedicines
Endeavor BioMedicines United States

Boldly pursuing development of transformational medicines that may restore hope for patients with in...

Series C
52 employees
Biotechnology, Health Care
Compare Vicore Pharma AB vs Endeavor BioMedicines
Vicore Pharma AB vs
Melius Pharma
Melius Pharma Sweden

Clinical stage biopharma company developing treatments for diseases with high unmet needs at a reduc...

Series A
3 employees
Health Care, Pharmaceutical
Compare Vicore Pharma AB vs Melius Pharma
Vicore Pharma AB vs
Aileron Therapeutics
Aileron Therapeutics United States

Developing novel medicines to provide better treatment options for patients with life-threatening pu...

Post Ipo Equity
17 employees
Biopharma, Biotechnology
Compare Vicore Pharma AB vs Aileron Therapeutics

FAQ About Vicore Pharma AB

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally...
Vicore Pharma AB was founded in 2009.
Vicore Pharma AB is headquartered in Sweden.
Vicore Pharma AB operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
Vicore Pharma AB has approximately 41 employees.
Vicore Pharma AB has completed 2 funding rounds, raising a total of $501.50M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Vicore Pharma AB include Endeavor BioMedicines, Melius Pharma, Aileron Therapeutics, Activaero GmbH, Trevi Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vicore Pharma AB and Endeavor BioMedicines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Vicore Pharma AB and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy